Experimental Study on Anti-angiogenesis in Mice with Sarcoma S-180 by Ginsenoside Rg3 Combined with Low-dose of Cyclophosphamide

Song Zheng,Wang Huaqing,Zhang Huilai

DOI: https://doi.org/10.3969/j.issn.1007-6948.2008.03.028

2008-01-01

Abstract:Objective To evaluate the anti-angiogenetic effect of the combination of ginsenoside Rg3 and low-dose cyclophosphamide(CTX) in mice with sarcoma S-180,and to observe the anti-tumor effect,toxicity,adverse reaction of the tumor bearing mice.Methods BALB/c sarcoma S-180 mice were taken as the model and randomly divided into 4 groups,i.e,the low-dose CTX(LDCTX) group,the ginsenoside Rg3(Rg3) group,the low-dose CTX combined with ginsenoside Rg3(LDCTX+ Rg3) group,and the model group.Tumor weight of mice,tumor microvascular density(MVD)and vascular endothelial growth factor(VEGF)gene expression were determined after the therapeutic course.Results In the LDCTX group,Rg3 group,LDCTX+ Rg3 group,tumor grew comparatively slower than in the model group(P<0.05),the tumor inhibitory effect was 36.12%,49.43% and 71.10% respectively.Compared with the model group,MVD and VEGF expression were lower in other three groups,and the lowering action was more significant when the two drugs were used in combination(P<0.05).The combined therapy of CTX and ginsenoside Rg3 resulted in better quality of mice life.Conclusion The combination of low-dose CTX and ginsenoside Rg3 has obvious synergetic action of anti-angiogenesis and shows significant tumor inhibitory effect,with less toxic and adverse reactions than the treatment of CTX alone.